Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Adds Tufts Heart Geneticist Ordovas to SAB; Diversa Brings on New SVP; Panvera Prez Leaves His Post

NEW YORK, Jan. 8-Tufts University geneticist Jose Ordovas has joined Perlegen Sciences' scientific advisory board, the company said in a statement today.

 

Ordovas, who is Professor of Nutrition and Genetics at Tufts, identifies and studies genes influencing blood lipids. His lab has been closely involved in the Framingham Heart Study, and is examining how genetic variation in different global population groups influences cardiovascular disease risk.

 

He will advise Perlegen in its efforts to understand the relationships between disease and genetic variation.

 


 

Diversa hired Edward Shonsey as senior vice president of internal development, the company said on Jan. 7.

 

Shonsey was previously with Syngenta, where he was involved in new product development and organizing R&D. He also has worked with Novartis and Pioneer Hi-Bred International.

           

Diversa is a San Diego-based company using genomics techniques to develop new agricultural, pharmaceutical and industrial products.

 


 

AnVil hired HIV expert Steven Henry as senior medical informaticist, the company said yesterday.

 

Henry has experience in bioinformatics, pharmacogenomics, genetic modeling, and direction of clinical trials. At GlaxoSmithKline, he was project leader for analysis of clinical pharmacology and genotype data, where he advised on the creation of genetic database systems in clinical research.

 

He was also medical/clinical project manager for FirstGenetic Trust.

 

AnVil is bioinformatics company based in Burlington, Mass.

 


 

Michael Wokasch left his post as president of Panvera to become COO of IMPAX, the Hayward, Calif.-based drug company said on Jan. 3.

 

At IMPAX, Wokasch will oversee manufacturing, packaging, engineering, materials management, warehousing, and human resources. Wokasch, 51, served on the board of IMPAX until his appointment as COO.

 

He will be replaced by Tom Schwei, general manager of the Vertex unit.

 

 


 

Bangalore-based bioinformatics company Strand Genomics appointed Todd Laird as senior vice president of business development.

 

Laird will be based in the company's San Francisco area office.

 

He was most recently VP of business development at life sciences middleware company GeneticXchange.

 


 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.